Name | TBI-166 |
---|
Description | TBI-166, a riminophenazine analogue, is an orally active anti-tuberculosis agent with fewer adverse reactions than the lead riminophenazine compound, Clofazimine (HY-B1046) [1][2][3]. |
---|---|
Related Catalog | |
In Vitro | TBI-166 抑制 M. tuberculosis H37Rv 复制 (MIC: 0.063 μg/mL),对 16 种药物敏感的临床分离株 (分枝杆菌属) 也有效,MIC 为 0.005-0.15μg/mL[1]。 TBI-166 (0-1 μg/mL,3 天) 抑制 M. tuberculosis 感染的 J774A.1 细胞内 M. tuberculosis[1]. |
In Vivo | TBI-166 (10-80 mg/kg,口服,8 周) 在慢性小鼠 M. tuberculosis H37Rv 感染模型中表现出抗结核活性[1]。 TBI-166 在小鼠体内显示出 LD50 值超过 3,000 mg/kg[1]。 TBI-166 的半衰期较短 (41.25 h),可降低皮肤色素沉着的可能性[2]。 Animal Model: Chronic murine M. tuberculosis H37Rv infected model[1] Dosage: 10, 20, 80 mg/kg Administration: Oral administration, 8 weeks. Result: Reduced CFU counts in lung. |
References |
Molecular Formula | C32H30F3N5O3 |
---|---|
Molecular Weight | 589.61 |